ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 168 filers reported holding ACCELERON PHARMA INC in Q2 2019. The put-call ratio across all filers is 1.56 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $344,000 | +37.1% | 2,000 | 0.0% | 0.01% | +33.3% |
Q2 2021 | $251,000 | -36.1% | 2,000 | -31.0% | 0.01% | -40.0% |
Q1 2021 | $393,000 | +5.9% | 2,900 | 0.0% | 0.02% | -11.8% |
Q4 2020 | $371,000 | -45.0% | 2,900 | -51.7% | 0.02% | -51.4% |
Q3 2020 | $675,000 | +1.2% | 6,000 | -14.3% | 0.04% | -5.4% |
Q2 2020 | $667,000 | +6.0% | 7,000 | 0.0% | 0.04% | -17.8% |
Q1 2020 | $629,000 | +48.3% | 7,000 | -12.5% | 0.04% | +87.5% |
Q4 2019 | $424,000 | -17.5% | 8,000 | -38.5% | 0.02% | -22.6% |
Q3 2019 | $514,000 | -3.7% | 13,000 | 0.0% | 0.03% | -6.1% |
Q2 2019 | $534,000 | +10.3% | 13,000 | +25.0% | 0.03% | +10.0% |
Q1 2019 | $484,000 | +6.8% | 10,400 | 0.0% | 0.03% | -3.2% |
Q4 2018 | $453,000 | -40.0% | 10,400 | -21.2% | 0.03% | -29.5% |
Q3 2018 | $755,000 | +15.3% | 13,200 | -2.2% | 0.04% | +12.8% |
Q2 2018 | $655,000 | +59.4% | 13,500 | +28.6% | 0.04% | +50.0% |
Q1 2018 | $411,000 | +20.9% | 10,500 | +31.2% | 0.03% | +23.8% |
Q4 2017 | $340,000 | – | 8,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Artal Group S.A. | 1,400,000 | $133,378,000 | 3.73% |
Foresite Capital Management III, LLC | 42,030 | $4,004,000 | 3.56% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 257,249 | $24,508,000 | 2.23% |
Cormorant Asset Management, LP | 600,000 | $57,162,000 | 2.18% |
Avoro Capital Advisors LLC | 1,040,000 | $99,081,000 | 1.96% |
QVT Financial LP | 101,396 | $9,660,000 | 1.64% |
FARALLON CAPITAL MANAGEMENT LLC | 2,100,000 | $200,067,000 | 1.60% |
Rhenman & Partners Asset Management AB | 155,000 | $14,767,000 | 1.60% |
Parkman Healthcare Partners LLC | 57,500 | $5,478,000 | 1.54% |
Ikarian Capital, LLC | 187,700 | $17,882,000 | 1.42% |